AMT raises €14 million to fund Glybera
This article was originally published in Scrip
Executive Summary
Amsterdam Molecular Therapeutics (AMT) has raised €14.3 million in gross proceeds through a private placement. AMT's main shareholders – Advent Venture Partners, Gilde Healthcare Partners, Credit Agricole Private Equity and Forbion Capital Partners –agreed to invest a total of €3.75 million. The rest of the placement was offered to the company's other investors and members of its board. Pursuant to the placement AMT will issue just under 8.5 million new shares for an offer price of €1.70 each.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.